Introducing ‘Health Vulnerability’. Towards a Human Right Claim for Innovative Orphan Drugs? - HAL Accéder directement au contenu
Article dans une revue European Journal of Health Law Année : 2020

Introducing ‘Health Vulnerability’. Towards a Human Right Claim for Innovative Orphan Drugs?

Résumé

Abstract Although several European law instruments specifically promote the development of orphan medicines, rare disease patients still suffer from an excessive lack of access to orphan drugs. In order to base a claim for equity of access to research benefits, health vulnerability is introduced as a human rights-based public health concept. It represents a potentially valuable and powerful means in European law for rare disease patients to claim for an improved public action to develop innovative orphan drugs, including through the use of novel data-driven technologies such as computer modelling and simulation, as they have the potential to palliate some of the obstacles in the current development process of orphan medicines. The human rights-based approach would be all the more valuable, as it would simultaneously draw attention on privacy aspects of vulnerability for orphan disease patients, especially regarding increased risks stemming from the processing of highly sensitive health data.

Domaines

Droit
Fichier principal
Vignette du fichier
Éloïse Gennet - Introducing ‘Health Vulnerability’. Towards a Human Right Claim for Innovative Orphan Drugs?.pdf ( 343.18 Ko ) Télécharger
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

halshs-03246136, version 1 (08-07-2023)

Identifiants

Citer

Éloïse Gennet. Introducing ‘Health Vulnerability’. Towards a Human Right Claim for Innovative Orphan Drugs?. European Journal of Health Law, 2020, 27 (3), pp.290-307. ⟨10.1163/15718093-BJA10005⟩. ⟨halshs-03246136⟩
27 Consultations
17 Téléchargements
Dernière date de mise à jour le 07/04/2024
comment ces indicateurs sont-ils produits

Altmetric

Partager

Gmail Facebook Twitter LinkedIn Plus